or Try an Advanced Search...

    Technical Analysis for ZURA - Zura Bio Limited

    Grade Last Price % Change Price Change
    C 6.00 15.61% 0.81
    ZURA closed up 15.61 percent on Thursday, May 16, 2024, on 1.11 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ZURA trend table...
    Date Alert Name Type % Chg
    Expansion Breakout Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Wide Range Bar Range Expansion 0.00%
    Wide Bands Range Expansion 15.61%
    Overbought Stochastic Strength 15.61%
    Up 3 Days in a Row Strength 15.61%
    Up 4 Days in a Row Strength 15.61%
    Expansion Breakout Bullish Swing Setup 16.28%
    Wide Bands Range Expansion 16.28%
    Overbought Stochastic Strength 16.28%
    Older End-of-Day Signals for ZURA ...

       Recent Intraday Alerts

    Alert Time
    Up 2 ATRs about 5 hours ago
    Up 10% about 5 hours ago
    Up 1 ATR about 8 hours ago
    60 Minute Opening Range Breakout about 8 hours ago
    Possible Pocket Pivot about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ZURA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody

    Is ZURA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 10 Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
    May 9 Zura Bio reports Q1 results
    May 9 Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
    Apr 25 Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)
    Apr 18 Zura Bio stock jumps on plans to raise $112.5M in private financing
    Apr 18 Zura Bio Announces Oversubscribed $112.5 Million Private Placement
    Apr 8 Zura Bio names new executive chief
    Apr 8 Zura Bio Announces Robert Lisicki as CEO and Director
    Apr 2 Insider Buyers At Zura Bio Recover Some Losses, But Still Down US$165k
    Mar 28 Zura Bio GAAP EPS of -$2.09 beats by $0.53
    See more ZURA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.9999
    52 Week Low 2.0
    Average Volume 358,962
    200-Day Moving Average 4.70
    50-Day Moving Average 3.52
    20-Day Moving Average 4.40
    10-Day Moving Average 4.91
    Average True Range 0.46
    RSI (14) 79.25
    ADX 44.7
    +DI 41.32
    -DI 7.98
    Chandelier Exit (Long, 3 ATRs) 4.81
    Chandelier Exit (Short, 3 ATRs) 4.38
    Upper Bollinger Bands 5.77
    Lower Bollinger Band 3.02
    Percent B (%b) 1.08
    BandWidth 62.62
    MACD Line 0.54
    MACD Signal Line 0.43
    MACD Histogram 0.1085
    Fundamentals Value
    Market Cap 258.56 Million
    Num Shares 43.1 Million
    EPS 0.15
    Price-to-Earnings (P/E) Ratio 40.00
    Price-to-Sales 0.00
    Price-to-Book 2.67
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.39
    Resistance 3 (R3) 7.30 6.75 7.16
    Resistance 2 (R2) 6.75 6.39 6.79 7.08
    Resistance 1 (R1) 6.37 6.17 6.56 6.46 7.00
    Pivot Point 5.82 5.82 5.91 5.86 5.82
    Support 1 (S1) 5.44 5.46 5.63 5.54 5.00
    Support 2 (S2) 4.89 5.24 4.94 4.92
    Support 3 (S3) 4.52 4.89 4.84
    Support 4 (S4) 4.61